AR095348A1 - Medios de cultivo celular y métodos de producción de anticuerpos - Google Patents

Medios de cultivo celular y métodos de producción de anticuerpos

Info

Publication number
AR095348A1
AR095348A1 ARP140101052A ARP140101052A AR095348A1 AR 095348 A1 AR095348 A1 AR 095348A1 AR P140101052 A ARP140101052 A AR P140101052A AR P140101052 A ARP140101052 A AR P140101052A AR 095348 A1 AR095348 A1 AR 095348A1
Authority
AR
Argentina
Prior art keywords
cell culture
culture media
antibody production
production methods
methods
Prior art date
Application number
ARP140101052A
Other languages
English (en)
Spanish (es)
Inventor
Mknight Nathan
Vijayasankaran Natarajan
Carvalhal Veronica
Feeney Lauren
Dirocco Thomas
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51537877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR095348(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR095348A1 publication Critical patent/AR095348A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
ARP140101052A 2013-03-15 2014-03-14 Medios de cultivo celular y métodos de producción de anticuerpos AR095348A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361801247P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095348A1 true AR095348A1 (es) 2015-10-07

Family

ID=51537877

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101052A AR095348A1 (es) 2013-03-15 2014-03-14 Medios de cultivo celular y métodos de producción de anticuerpos

Country Status (12)

Country Link
US (5) US9441035B2 (enExample)
EP (1) EP2968544A4 (enExample)
JP (2) JP2016513478A (enExample)
KR (1) KR102202476B1 (enExample)
CN (1) CN105246510A (enExample)
AR (1) AR095348A1 (enExample)
BR (1) BR112015022529A2 (enExample)
CA (1) CA2903589A1 (enExample)
HK (1) HK1213179A1 (enExample)
MX (1) MX366112B (enExample)
RU (1) RU2015144020A (enExample)
WO (1) WO2014145091A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012001742A (es) 2009-08-11 2012-03-21 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
AR104050A1 (es) 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
KR102595048B1 (ko) * 2016-11-07 2023-10-26 씨젠 인크. 조작된-시스테인 캡의 분포
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
EP3727629A1 (en) 2017-12-22 2020-10-28 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
CN108823267B (zh) * 2018-06-25 2020-05-08 深圳市菲鹏生物制药股份有限公司 调节cho-k1表达系统所分泌抗体的酸性峰含量的方法
US20240043486A1 (en) * 2020-12-08 2024-02-08 Partner Therapeutics, Inc. Manufacture of granulocyte macrophage-colony stimulating factor
CN116635416A (zh) * 2020-12-22 2023-08-22 诺华股份有限公司 用于在细胞培养期间降低分泌的重组表达蛋白质中半胱氨酸残基的氧化水平的方法
WO2022233770A1 (en) * 2021-05-03 2022-11-10 Boehringer Ingelheim International Gmbh Method for producing spesolimab
AU2023250258A1 (en) * 2022-04-06 2024-11-14 Kashiv Biosciences, Llc An improved cell culture process for production of protein
EP4587552A1 (en) * 2022-11-09 2025-07-23 Infors AG Incubator avoiding condensation

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0921855B1 (en) 1996-08-30 2003-11-19 Upfront Chromatography A/S Isolation of immunoglobulins
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ATE293640T1 (de) 1997-04-07 2005-05-15 Genentech Inc Anti-vegf antikörper
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
DE60039596D1 (de) 1999-03-30 2008-09-04 Japan Tobacco Inc Verfahren zur herstellung von monoklonalen antikörpern
DE60031999T2 (de) 1999-10-04 2007-06-06 Novartis Vaccines and Diagnostics, Inc., Emeryville Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
NZ526173A (en) * 2000-11-06 2005-03-24 Invitrogen Corp Dry powder cells and cell culture reagents and methods of production thereof
CA2447114A1 (en) 2001-05-16 2002-11-21 Abgenix, Inc. Human antipneumococcal antibodies from non-human animals
WO2003046162A2 (en) * 2001-11-28 2003-06-05 Polymun Scientific Immunbiologische Forschung Gmbh Process for the production of polypeptides in mammalian cell cultures
CN1703233A (zh) 2002-07-12 2005-11-30 米德列斯公司 防止蛋白氧化降解的方法和组合物
CN1761482A (zh) 2003-01-17 2006-04-19 纽约州立大学研究基金会 与胰腺癌相关的抗原、针对它的抗体以及诊断和治疗方法
US7456264B2 (en) 2003-05-21 2008-11-25 Medarex, Inc. Human monoclonal antibodies against Bacillus anthracis protective antigen
US20060115901A1 (en) * 2004-10-22 2006-06-01 Bahram Valamehr Method and media for single cell serum-free culture of CHO cells
US8530192B2 (en) * 2005-02-11 2013-09-10 Novo Nordisk Healthcare Ag Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
CN100362098C (zh) * 2005-09-29 2008-01-16 华东理工大学 适用于多种动物细胞大规模培养的无血清培养基
JP4976502B2 (ja) * 2007-10-15 2012-07-18 中外製薬株式会社 抗体の製造方法
EP2334323A2 (en) 2008-09-10 2011-06-22 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
KR20110074564A (ko) * 2008-09-24 2011-06-30 메디뮨 엘엘씨 세포 배양, 바이러스 증식 및 바이러스 정제를 위한 방법
JP5749930B2 (ja) * 2008-10-28 2015-07-15 中外製薬株式会社 ペプチド含有動物細胞培養用培地
CN101603026B (zh) * 2009-06-19 2011-01-19 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
CN102471377B (zh) * 2009-07-24 2015-04-22 霍夫曼-拉罗奇有限公司 优化抗体的生产
MX2012001742A (es) * 2009-08-11 2012-03-21 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
WO2011091350A2 (en) * 2010-01-25 2011-07-28 Ventria Bioscience Methods & compositions for improving protein production
US9133493B2 (en) * 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US8956830B2 (en) * 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture

Also Published As

Publication number Publication date
MX366112B (es) 2019-06-26
HK1213179A1 (zh) 2016-06-30
US9441035B2 (en) 2016-09-13
US20200347122A1 (en) 2020-11-05
KR102202476B1 (ko) 2021-01-12
US20160102141A1 (en) 2016-04-14
CA2903589A1 (en) 2014-09-18
MX2015011781A (es) 2016-04-04
EP2968544A4 (en) 2016-10-12
RU2015144020A (ru) 2017-04-21
BR112015022529A2 (pt) 2017-07-18
US20200291103A1 (en) 2020-09-17
US20170051049A1 (en) 2017-02-23
CN105246510A (zh) 2016-01-13
JP2019193643A (ja) 2019-11-07
JP2016513478A (ja) 2016-05-16
US20140308273A1 (en) 2014-10-16
KR20150131258A (ko) 2015-11-24
WO2014145091A1 (en) 2014-09-18
EP2968544A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
ECSP14005975A (es) Anticuerpos anti-PHF-tau y sus usos
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
CR20160147A (es) Formulaciones de anticuerpos
MX2015013202A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
MX2018014043A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
MX2019008065A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
MX391041B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
AR103161A1 (es) Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
AR095774A1 (es) Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos
CO6771458A2 (es) Conjugados de anticuerpo-fármaco
NI201300080A (es) Formas sólidas de 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona, y sus composiciones farmacéuticas y usos
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
CO2017002253A2 (es) Compuesto dirigido a il-23a y tnf-alfa
BR112015030946A8 (pt) composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
MX376437B (es) Uso de hígado descelularizado por perfusión para recelularización de células de islote.
BR112014026308A2 (pt) composições de cultura celular e métodos para produção de polipeptídeos
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
MX2015012168A (es) Expansión de celulas madre adultas in vitro.

Legal Events

Date Code Title Description
FB Suspension of granting procedure